EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions

Gedion Mengistu iD

The Journal of Gene Medicine · 2026-04 · 28 (4)

DOI: 10.1002/jgm.70091 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Gene Medicine, online erschienen am 08.04.2026. Verfasst von Gedion Mengistu. Beteiligte Einrichtung: Department of Biotechnology, Arba Minch University, Arba Minch, Ethiopia. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Genetic Therapy, Gene Editing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR–Cas systems have emerged as versatile platforms for targeted genome and transcriptome engineering, enabling precise manipulation of disease‐associated genetic pathways. Continued advances in CRISPR technologies including base editing, prime editing, and epigenome modulation have expanded therapeutic possibilities beyond nuclease‐mediated DNA cleavage, allowing programmable gene correction and regulation. Early clinical studies demonstrate sustained therapeutic benefit in selected monogenic disorders and highlight the feasibility of both ex vivo and in vivo editing strategies. However, clinical translation remains constrained by challenges such as off‐target activity, delivery inefficiency, immune responses to Cas proteins, editing heterogeneity, and uncertainties regarding long‐term safety. This review critically synthesizes recent advances in CRISPR–Cas systems for human disease therapy, integrating molecular innovations, delivery strategies, clinical progress, and ethical considerations. By evaluating both technological achievements and unresolved limitations, this article outlines key priorities for advancing CRISPR‐based therapeutics toward safe, effective, and equitable precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGenetic TherapyGene EditingHumansAnimalsPrecision MedicineEpigenome Editing

Stichwörter der Autor:innen

CRISPR–Cas systemsbase editingcancer immunotherapydelivery systemsgene therapygenome editinginfectious diseasesmonogenic disordersoff‐target effectsprime editing

Autor:innen und Institutionen

  • Department of Biotechnology, Arba Minch University, Arba Minch, Ethiopia.

ORCID-Profile: Gedion Mengistu

Zitieren

APA

Mengistu, G. (2026). CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions. The Journal of Gene Medicine, 28(4). https://doi.org/10.1002/jgm.70091

Vancouver

Mengistu G. CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions. The Journal of Gene Medicine. 2026;28(4). doi:10.1002/jgm.70091

BibTeX
@article{Mengistu2026,
  author = {Mengistu, Gedion},
  title = {CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions},
  journal = {The Journal of Gene Medicine},
  year = {2026},
  volume = {28},
  number = {4},
  doi = {10.1002/jgm.70091}
}
Kostenlos starten →